Often seen in Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), arise as a consequence of immune system involvement and can have myriad health consequences. Both CIDP and MMN are characterized by complex presentations and frequent misdiagnoses. CIDP shows gradual peripheral nerve demyelination, leading to weakness and sensory loss, while MMN presents with asymmetric weakness devoid of sensory complications. With an array of treatment options, managing polyneuropathy in CIDP and MMN can be challenging. This collaborative platform serves as a unifying space for healthcare providers, facilitating the exchange of insights and elevating the standard of care for patients affected by CIDP and MMN. In this learning activity, you will learn how to enhance the lives of CIDP and MMN patients via a program promoting local and cross-community support, driving effective practice-sharing for better outcomes.
CME/CE Accreditation Information
Hereditary angioedema (HAE) is a rare but potentially life-threatening disease affecting approximately 1 in 67,000 individuals, with no identified differences in prevalence due to sex or ethnicity. The disease commonly presents with recurrent attacks of swelling in any part of the body. Given the physical and psychosocial impact of HAE on patients and their families, many patients benefit from effective long-term prophylaxis. However, there are numerous clinical gaps impacting the initiation of effective HAE prophylaxis. This collaborative social learning platform aims to help close those gaps by establishing a network of providers who can connect with and support each other with the aim of learning and sharing best practices that will improve outcomes for patients needing long term HAE prophylaxis. By immersing learners in a personalized educational experience, this program explores the management of HAE in a way that is both informative and practical.
CME/CE Accreditation Information
Spinal muscular atrophy (SMA) can be a debilitating condition causing immobility, respiratory difficulties, and reduced lifespan. But with the advent of new disease-modifying therapies, the prognosis for patients with SMA has been completely altered. These treatments may help patients live longer, creating unique clinical needs. Adults now make up more than a quarter of patients with SMA. However, there are no specific guidelines for the assessment and treatment of adult patients, leading to gaps in their diagnosis and management. Adult care is complex and requires multidisciplinary care. This collaborative CME provides the opportunity to learn and share best practices that will improve outcomes for patients with SMA.
CME/CE Accreditation Information
Welcome to our interactive and engaging educational initiative on managing anemia in myelodysplastic syndromes (MDS). Anemia is a common issue in MDS, causing symptoms like fatigue, pallor, shortness of breath, and light-headedness. It can have a significant impact on patients' quality of life and lead to complications such as iron overload and red blood cell transfusion dependence. Moreover, anemia and transfusion dependence are associated with poor outcomes in MDS. In this program, you will learn the optimal time to initiate anemia treatment, how best to dose luspatercept and address adverse events, and familiarize yourself with emerging data in the treatment of anemia related to low-risk MDS to better help your patients.
CME/CE Accreditation Information
